About Us
Overview
Team
Leadership Team
Board of Directors
Milestones
Radio Therapeutics
Pipeline
Programs
UniRDC
TM
Radio Technology
Manufacturing
Logistics
Partnering
Media
Press Releases
Full-Life Technologies Launches with $10M Seed Round Financing to Advance Its Nuclear Technology & Nuclear Medicines Businesses
Full-Life Technologies Announces Senior Executive Team Appointments
Full-Life Technologies Completes $37 Million (USD)Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production
Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals
Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round
Full-Life Technologies and Eckert & Ziegler Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
Full-Life Technologies will present preclinical data of its novel PSMA-targeted RDC program
225
Ac-FL-020 at the AACR Annual Meeting 2024
Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction
Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program
225
Ac-FL-020 at the AACR Annual Meeting 2024
Full-Life Technologies will showcase preclinical data of its NTSR1-targeted RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
Full-Life Technologies Announces Clearance from FDA of IND Application for
225
Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting
Full-Life Technologies Granted FDA Fast Track Designation for
225
Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors
Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors
Full-Life Technologies Attends the Morgan Stanley 22nd Annual Global Healthcare Conference
Full-Life Technologies to Present Three Top Rated Oral Presentations at the 37th Annual Congress of the European Association of Nuclear Medicine
Full-Life Technologies Announced the Progress of its Radioisotope Manufacturing Facility in Belgium
Full-Life Technologies to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Media Reports
FIERCE Biotech | Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D
ENDPOINTS NEWS | With ops spanning Belgium and China, Full-Life inks $245M buyout to beef up radiopharma pipeline
ENDPOINTS NEWS | Trailing Novartis and Eli Lilly, radiopharmaceuticals startup Full-Life Technologies nabs $63M to test new PSMA drug
Presentation
225
Ac-FL-020 is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity
Development of
177
Lu-FL-091 for the treatment of NTSR1-positive cancers
Career
Contact